Trial Profile
Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2015
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Adverse reactions
- 06 Mar 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov
- 04 Mar 2014 According to ClinicalTrials.gov record, planned end date changed from 1 Aug 2014 to 1 Aug 2015.
- 04 Mar 2013 Planned end date changed from 1 Aug 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.